Treatment with immune-suppressing myeloid-derived suppressor cells alongside JadiCell — an investigational stem cell therapy from Therapeutic Solutions International (TSOI) for chronic obstructive pulmonary disease (COPD) — led to more significant reductions in lung damage in mice compared with either treatment alone. Using them together also enhanced pulmonary regeneration…
Therapeutic Solutions International has filed a patent covering the therapeutic use of JadiCells — a type of mesenchymal stem cell derived from cells lining the umbilical cord — and its various combinations in treating chronic obstructive pulmonary disease (COPD). The patent application is supported by new data indicating…
AB569, Arch Biopartners’ lead therapy candidate, has received a U.S. patent for the treatment of chronic lung infections in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Patent 9,925,206 was issued by the U.S. Patent and Trademark Office to the University of Cincinnati, which previously granted…
Pulmatrix was granted an important patent from the European Union (EU) for its proprietary iSPERSE technology, a platform for inhaled drug delivery based on unique properties developed for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD). “This new patent shows our continued ability to obtain patents that protect…
Get regular updates to your inbox.